clinical trial · NCT03938246
Study of TVB-2640 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)TVB-2640 25 mg (US)TVB-2640 50 mg (US)Placebo (US)TVB-2640 50 mg (China)Placebo (China)TVB-2640 75 mg (US)
brief summary
This is a Phase 2 multi-center, randomized, single-blind, placebo-controlled study to evaluate the safety and efficacy of TVB-2640 in subjects with non-alcoholic steatohepatitis (NASH), a type of fatty liver disease. Subjects will be randomly assigned to 1 of 2 treatment groups (TVB-2640 at one of three doses or placebo). Following randomization, subjects will begin the 12-week treatment period and will receive once daily TVB-2640 or placebo.
started
Mar 22, 2019
primary completion
Oct 2, 2021
completion
Oct 2, 2021
last updated
Dec 19, 2024
official title
A Phase 2, Multi-Center, Single-Blind, Randomized, Placebo-Controlled Study of TVB-2640 in Subjects With Non-Alcoholic Steatohepatitis (FASCINATE-1)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol